Ainos, Inc. announced that it is initiating the second phase of co-development of a volatile organic compound (VOC) sensing platform, powered by AI Nose technology, in collaboration with Nisshinbo Micro Devices Inc. (NISD) and Taiwan Inabata Sangyo Co. (Inabata). The parties aim to finalize the prototype in the third quarter of 2024 and subsequently prepare for mass production.

In the second phase, the parties plan to finalize the platform's functionality, specifications, and market positioning for the platform. In addition, the parties will also focus on developing the solution's key hardware and software aspects, including manufacturing, form factor, user interface, and safety requirements. Under the co-development, Ainos and NISD will co-develop a VOC sensing platform that leverages Ainos' digital nose intellectual properties, the AI Nose platform.

The co-developed platform is intended to be used in a variety of applications including telehealth, automotive, industrial, and environmental safety. Inabata will provide business logistics for the program and liaise between Ainos and NISD. The Parties have a shared vision for the future of VOC sensing technology across a variety of applications, including telehealth, automotive, Industrial, and environmental safety.

The Company's actual results may differ materially from those indicated in the forward-looking statements. important factors that could cause the Company's actual results to differ materially from those indicated in The forward-looking statements. Important factors that could cause the Company' actual results to differ materially from the projections, forecasts, estimates and expectations discussed in this release include, among others, the cost of production and sales potential of the planned drug treatments announced in this press release; the Company's limited cash and history of losses; the Company's ability to raise additional capital to continue the Company's product development; the ability to accurately predict the future operating results of the Company; the ability to advance Ainos' current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates the Company develops; the ability to obtain and maintain regulatory approval of Ainos product candidates; delays in completing the development and commercialization of the Company's current and future product candidates, which could result in increased costs to the Company, delay or limit the ability to generate revenue and adversely affect the business, financial condition, results of operations and prospects of the Company; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; disruption in research and development facilities; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; potential cybersecurity attacks; increased requirements and costs related to cybersecurity; the Company's ability to realize the benefits of third party licensing agreements; the Company's ability to obtain and maintain intellectual property protection for Ainos product candidates; compliance with applicable laws, regulations andtariffs; and the Company's success in managing the growth.

A more complete description of these risk factors are expected to be a new product candidate.